BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

NCT01512251 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

BRAF Mutant Metastatic Melanoma

Interventions

DRUG: BKM120 Combined with Vemurafenib (PLX4032)

Sponsor

University of California, San Francisco

Collaborators

[object Object]